

Case Report

Duodenal Gastrointestinal Stromal Tumor

Divya Teja Patil<sup>1</sup>, Anil Kumar Sakalecha<sup>1\*</sup>, Parameshwar Keerthi B.H<sup>1</sup>, Yashas Ullas L.<sup>1</sup>

1.Department of Radio-Diagnosis, Sri Devaraj Urs Medical collage, Tamaka, Kolar.

Abstract

Gastrointestinal stromal tumors (GIST) are nonepithelial tumors arising from the interstitial cells of Cajal. They express KIT protein-CD117 on immunohistochemistry. GIST can arise anywhere in the GIT, including the mesentery, omentum, and retroperitoneum. In the duodenum, 2<sup>nd</sup> or 3<sup>rd</sup> part of duodenum is the most common site. Imatinib is the drug of choice and surgical resection is the main modality of treatment.

**Keywords:** Gastrointestinal Stromal Tumor.

Introduction:

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract (GIT). They account for ~5% of all sarcomas, and are mostly found in stomach and mid/distal small bowel.

Epidemiology:

GISTs are rare as compared to carcinoma. Mostly seen in older age group. Incidence is equal in both males and females. Can arise anywhere along the GIT. Most common site is stomach. In duodenum, the incidence is ~ 5 to 10 %. They are believed to arise from the interstitial cells of Cajal 2-3, with 95% staining positive for CD117 (c-KIT) and 70% for CD34. Three different types are recognised: Spindle cell GIST (70%), epithelioid cell GIST (20%), mixed (10%)

Case Report:

A 42 year old male came with generalized weakness and upper abdominal pain, increasing for 2 months and multiple episodes of vomiting and bleeding per rectum for 1 week. No past history.

On USG, a large well-defined mass was seen in right hypochondrium measuring ~ 10.8 x 9.1 x 8.6 cm. The lesion shows central hypo to anechoic areas suggestive of necrotic degeneration. On colour Doppler, the lesion shows central and peripheral vascularity. On CT, a large, well-defined heterogeneously enhancing exophytic mass measuring ~10.4 x 9.0 x 11.1 cm

(anteroposterior x transverse x craniocaudal) noted in the lateral wall of 2nd part of duodenum with luminal narrowing. Few arterial feeders are arising from common hepatic artery. Mass effect in the form of displacement of bowel loops inferiorly & inferior vena cava posteriorly. Few peripheral calcifications noted. Antero-laterally, there is focal adhesion of segment VI of liver. Posteriorly, the lesion is abutting & displacing the right kidney superiorly, however no infiltration seen. Supero-medially, the lesion is focally abutting the head of pancreas, however, no obvious infiltration noted. On lateral decubitus study, the contrast is seen entering from the lumen into the lesion with few air pockets.

In view of the above findings and supportive clinical history, features of duodenal GIST was given.

On post-operative biopsy specimen, spindle cells with eosinophilic cytoplasm within and variably hyalinised or edematous stroma was noted, which are specific for gastrointestinal stromal tumour.




Fig 1- A large soft tissue density lesion with central anechoic components in right hypochondrium.

Fig 2 – The lesion shows peripheral and internal vascularity on CDI.

Fig 3 – On plain CT, the lesion appears heterogenous with a calcification focus.

FIG 4 – CECT abdomen axial section, the lesion shows heterogenous enhancement.

\*Corresponding Author

Dr. Anil Kumar Sakalecha

Professor, Department of Radio-Diagnosis,  
Sri Devaraj Urs Medical College,  
Sri Devaraj Urs Academy of Higher Education and Research,  
Tamaka, Kolar -563101

Mobile No : 9844092448

E-mail: radiology@sduc.ac.in

Conflict of Interest: None

Financial Aid: Nil




Fig 5 – CECT abdomen coronal reformed image showing the lesion arising from 2<sup>nd</sup> part of duodenum.

Fig 6 – On lateral decubitus study, the contrast is seen entering the mass. Few airfoci are also seen in the mass.




Fig 7 & 8 - Spindle cells with eosinophilic cytoplasm within variably hyalinized or edematous stroma (Fig 8 – zoomed in image)

#### Discussion:

Gastrointestinal stromal tumours are the non-epithelial tumours arising from the interstitial cells of Cajal. 80% of malignant duodenal GISTs are located in the second or third portion of the duodenum.

The clinical findings vary depending on the location and size of the tumour at presentation. If the tumour is small, it may be only an incidental finding during radiological imaging or surgery for some other cause, whereas a large exophytic lesion may present as an abdominal mass due to its large size.

#### Imaging findings:

##### Barium studies:

Smooth, discrete mass with filling defect when ulcerations are present.

Substantial extraluminal component, only seen on cross-sectional imaging.

#### CT:

Because most of these tumours are submucosal in location, they usually attain a large size without causing bowel obstruction by the time of diagnosis. [5] Burkill et al. reported a mean diameter of 13 cm in their 116 cases of GIST. The margins of these tumours are well defined in about two-thirds of the cases.

Many of these tumours have an exophytic component as they arise from the muscularis propria. Marla et al.[6] found that all tumours in their study were predominantly exophytic, except for four cases where the primary tumour could not be categorized because of extensive metastatic spread.

They appear as exophytic, heterogeneous lesion with central non-enhancing necrotic areas within.

The enhancement pattern can vary from homogeneously enhancing to heterogeneously enhancing, with or without ulceration. Lee et al. found GIST to be well-defined tumours with homogenous enhancement, while Levy et al., [7] found large heterogeneously enhancing masses due to areas of necrosis or cystic degeneration. They described ulceration as a common feature of GIST.

Metastases from GIST commonly occur to the liver and peritoneal cavity via hematogenous spread and peritoneal seeding. Occasionally, metastases occur to soft tissues, lungs, and pleura. Marla et al. also found that tumours that enhanced homogeneously (nine out of 53 cases in their series) showed no metastases when they were followed for a mean period of 2.6 years as compared with those that enhanced heterogeneously. According to Nilsson et al., [8] at least 50% of these tumours have metastasis at presentation.

#### Treatment:

##### Surgical resection

Imatinib is a new chemotherapeutic agent used in the treatment of GIST. It is a molecularly targeted tyrosine kinase receptor blocker. Response to imatinib is usually good, with improved long-term survival. The imaging features in patients showing response to imatinib include decrease in the density of the lesion, reduction in enhancement, and reduction in the number of nodules and number of vessels. The size of the lesion may increase or decrease. King et al. also demonstrated cystic degeneration and involution of hepatic metastases on treatment with imatinib

#### Conclusion:

To conclude, the GIST is the most common stromal tumor in GIT with incidence of 5 to 10 % in duodenum. USG is the first modality and CECT is the imaging modality of choice for diagnosis. Also helps in the monitoring the disease during and after treatment.

#### References:

1. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miett

## Divya Teja Patil et al. Duodenal Gastrointestinal Stromal Tumor

- inen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. *Radiographics. Radiographics* 2003;23:283-304.
2. Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease. *Shock* 2005;23:482-3.
3. Burkill GJ, Badran M, Al-Muderis O, Thomas JM, Judson IR, Fisher C, et al. Malignant gastrointestinal stromal tumor: Distribution, imaging features, and pattern of metastatic spread. *Radiology* 2003;2:527-32.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001;1:1-12.
5. King DM. The radiology of gastrointestinal stromal tumours (GIST). *Cancer Imaging* 2005;5:150-6.
6. Hersh MR, Choi J, Garsett C, Clark R. Imaging Gastrointestinal stromal tumours. *Cancer Control* 2005;12:111-5.
7. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: Radiologic features with pathologic correlation. *Radiographics* 2003;2:283-304.
8. Nilsson B, Bümning P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: A population-based study in western Sweden. *Cancer* 2005;4:821-9.